PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Symptom | C0011849|diabetes mellitus |
| Sentences | 78 |
| PubMedID- 22111038 | It is well established that chronic hyperglycemia in patients with type 2 diabetes mellitus causes progressive deterioration of β-cell function. |
| PubMedID- 21886908 | From the previous results, it was concluded that the presence of type 2 diabetes mellitus-induced hyperglycemia results in significant increase in lipid profile, oxidative stress markers and inflammatory mediators in patients with non alcoholic fatty liver disease and normal liver function tests. |
| PubMedID- 23209008 | Finally, it attempts to integrate these mechanisms into the schema of pathophysiological factors that combine to produce hyperglycemia in patients with diabetes mellitus. |
| PubMedID- 24808678 | 5 complications due to hyperglycemia in diabetes mellitus can be prevented by using rational use of oral antidiabetic drugs (oads) and insulin. |
| PubMedID- 24717767 | Abnormal regulation of glucagon secretion has been implicated in the development of hyperglycemia in patients with type 2 diabetes mellitus , and a recent study in animal models indicated that a reduction in glucagon action can have profound effects on mitigating hyperglycemia even in the presence of severe hypoinsulinemia . |
| PubMedID- 26528798 | Skeletal muscle is the principal site for postprandial glucose utilization and augmenting the rate of glucose utilization in this tissue may help to control hyperglycemia associated with diabetes mellitus. |
| PubMedID- 26343954 | Enhanced oxidative stress and hyperglycemia are associated with diabetes mellitus (dm). |
| PubMedID- 26379785 | Chronic hyperglycemia in diabetes mellitus is known to induce numerous chronic complications including micro- and macrovascular injuries, whose diagnosis is often hampered by silent or minor clinical presentation. |
| PubMedID- 21217061 | hyperglycemia in diabetes mellitus promotes oxidative stress in endothelial cells, which contributes to development of cardiovascular diseases. |
| PubMedID- 21046527 | Aleglitazar, being developed by roche holding, is a dual agonist for ppargamma and pparalpha for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26253538 | Secondly, we sought to investigate the effect of glp-1 modulation on myocardial function in the setting of hyperglycemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 23633864 | The oxidative degradation of fructosamines may contribute to the oxidative stress found in hyperglycemia associated with diabetes mellitus. |
| PubMedID- 24858947 | hyperglycemia resulting from type 2 diabetes mellitus (t2dm) is the main cause of diabetic complications such as retinopathy and neuropathy. |
| PubMedID- 22128218 | It has been shown that the hyperglycemia associated with diabetes mellitus results in the activation of neutrophils(51) and that this activation contributes to an increase in oxidative stress that is partly responsible for diabetes complications. |
| PubMedID- 25317173 | Early macrovascular atherosclerosis may play a crucial role in subtle brain atrophy in type 2 diabetes mellitus patients, with chronic hyperglycemia playing a lesser role. |
| PubMedID- 22196774 | His laboratory blood values showed a non-regulated diabetes mellitus with hyperglycemia of 32 mmol/l, white blood cell count of 18 × 109/l with 81.6% polymorphonuclear cells (pmns), elevated c-reactive protein (crp), hemoglobin, sodium and creatinine. |
| PubMedID- 25651730 | Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 25767499 | hyperglycemia in diabetes mellitus can inhibit akt activation or accelerate akt deactivation, and reduce akt phosphorylation by activating the c-jun n-terminal kinase pathway. |
| PubMedID- 23220949 | Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. |
| PubMedID- 21341505 | Nonenzymatic glycation of proteins or maillard reaction is increased in diabetes mellitus due to hyperglycemia and leads to several complications such as blindness, heart disease, nerve damage and kidney failure. |
| PubMedID- 21713142 | Experimental diabetes mellitus-induced hyperglycemia produced a significant decrease in tail flick latency time. |
| PubMedID- 23315305 | The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (t2dm) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. |
| PubMedID- 25307034 | Our recommendations include: terminology revision from new-onset diabetes after transplantation to posttransplantation diabetes mellitus (ptdm), exclusion of transient posttransplant hyperglycemia from ptdm diagnosis, expansion of screening strategies (incorporating postprandial glucose and hba1c) and opinion-based guidance regarding pharmacological therapy in light of recent clinical evidence. |
| PubMedID- 23231438 | In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (t2dm) and were associated with weight loss. |
| PubMedID- 23116444 | The term diabetic cardiomyopathy refers to a state of cardiac dysfunction independent of associated coronary artery disease that arises within weeks of hyperglycemia (hg) leading to longer term diabetes mellitus (dm) 1. |
| PubMedID- 23250800 | Our aim was to determine if increased nitric oxide generation by l-arginine infusion would reverse this deleterious response to clamped hyperglycemia in women with type 1 diabetes mellitus. |
| PubMedID- 22260979 | Although hyperglycemia associated with diabetes mellitus is well known to enhance ros production in vascular endothelial cells, the effects of either acute or chronic high glucose environments on neurons and glial cells remain unclear. |
| PubMedID- 23594031 | Aim: the purpose of this study is to evaluate continuous glucose monitoring (cgm) in predicting diabetes mellitus in children with incident hyperglycemia (ih) and negativity for some insular autoantibodies. |
| PubMedID- 23454717 | Non-enzymatic glycation, which refers to the spontaneous binding of reducing sugars to free amino groups, is increased in diabetes mellitus because of hyperglycemia and is amplified by oxidative processes ('glycoxidation'). |
| PubMedID- 22911800 | hyperglycemia in diabetes mellitus damages blood vessels and induces vascular complications in the retinal, renal, and cardiovascular tissues . |
| PubMedID- 20876838 | Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. |
| PubMedID- 21931813 | Also increasing in incidence is type ii diabetes mellitus (t2d), associated with hyperglycemia, insulin-resistance, and hyperlipidemia , 7. |
| PubMedID- 20649531 | diabetes mellitus (dm), a state of chronic hyperglycemia, is associated with a variety of serious complications. |
| PubMedID- 22247912 | Although the kidney becomes a victim of hyperglycemia in diabetes mellitus, recent work has shown that the abnormalities of lipid and glucose metabolism in the kidney are similarly important to those in adipose tissue. |
| PubMedID- 24516103 | Dipeptidyl peptidase-4 inhibitors prevent the degradation of incretin hormones and reduce postprandial hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 22247866 | Several drugs such as biguanides and sulfonylureas are presently available to reduce hyperglycemia in diabetes mellitus. |
| PubMedID- 22611498 | Endothelial dysfunction associated with insulin resistance appears to precede the development of overt hyperglycemia in patients with type 2 diabetes mellitus . |
| PubMedID- 25422773 | Diabetic peripheral neuropathy (dpn) is a well-known microvascular complication of type 2 diabetes mellitus attributed to chronic hyperglycemia, and is defined as the presence of peripheral nerve dysfunction in diabetics after exclusion of other causes3–6. |
| PubMedID- 23816355 | Exercise has been widely recognized to ameliorate insulin resistance and hyperglycemia in individuals with type 2 diabetes mellitus (t2dm) . |
| PubMedID- 24348462 | Overt diabetes mellitus – with hyperglycemia and severe insulin deficiency as prominent features – can be considered a disorder of domestication in that affected cats would die without treatment. |
| PubMedID- 22071577 | diabetes mellitus, a state of persistent hyperglycemia, is a major cause of micro- and macrovascular diseases. |
| PubMedID- 26024569 | Purpose: although newer agents (dipeptidyl peptidase dpp-4 inhibitors and glucagon-like peptide glp-1 receptor agonists) are available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (t2dm), the impact of the availability of these agents on the use of second-generation sulfonylureas (sus) is unknown. |
| PubMedID- 22842610 | Self-monitoring of blood glucose is the standard of care in management of hyperglycemia among patients with diabetes mellitus. |
| PubMedID- 22745633 | hyperglycemia in individuals with diabetes mellitus usually compromises myocardial contractile function and energy metabolism independent of macro- and microvascular coronary anomalies . |
| PubMedID- 25633134 | Among the many complications of type 2 diabetes mellitus (t2dm) arising from prolonged hyperglycemia, as well as from comorbid conditions such as hypertension, is chronic kidney disease (ckd), which is present in up to 40% of patients with t2dm 1. |
| PubMedID- 21307777 | Aim: hyperglycemia in diabetes mellitus (dm) may be one of the most important factors responsible for the development of oxidative stress, which promotes the main complications in dm patients. |
| PubMedID- 25927597 | In recent years, selective sglt2 inhibitors have been developed and are now in clinical use for the treatment of hyperglycemia in patients with type 2 diabetes mellitus . |
| PubMedID- 25284699 | Glucagon-like peptide-1 receptor (glp-1) agonists and dipeptidyl-peptidase-4 (dpp-4) inhibitors are therapies that are used to treat hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 21521130 | Introduction: in preliminary clinical studies, aleglitazar, a new dual ppar-alpha-gamma agonist, has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. |
| PubMedID- 22699799 | hyperglycemia occurs in patients with poorly controlled diabetes mellitus and contributes to bone resorption and increased susceptibility to bacterial infections. |
Page: 1 2